Pedro L Moro1, Janet Cragan2, Naomi Tepper3, Yenlik Zheteyeva4, Oidda Museru5, Paige Lewis5, Karen Broder5. 1. Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and Prevention (CDC), <add>1600 Clifton Road, MS D26</add>, Atlanta, GA 30333, USA. Electronic address: pmoro@cdc.gov. 2. Birth Defects Branch, Division of Birth Defects and Developmental Disabilities, National Center on Birth Defects and Developmental Disabilities (NCBDDD), CDC, Atlanta, GA 30333, USA. 3. Women's Health and Fertility Branch, Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), CDC, Atlanta, GA 30333, USA. 4. Community Interventions for Infection Control Unit, Division of Global Migration and Quarantine, CDC, Atlanta, GA 30333, USA. 5. Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and Prevention (CDC), <add>1600 Clifton Road, MS D26</add>, Atlanta, GA 30333, USA.
Abstract
BACKGROUND: In October 2011, the Advisory Committee on Immunization Practices (ACIP) issued updated recommendations that all pregnant women routinely receive a dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. OBJECTIVES: We characterized reports to the Vaccine Adverse Event Reporting System (VAERS) in pregnant women who received Tdap after this updated recommendation (2011-2015) and compared the pattern of adverse events (AEs) with the period before the updated recommendation (2005-2010). METHODS: We searched the VAERS database for reports of AEs in pregnant women who received Tdap vaccine after the routine recommendation (11/01/2011-6/30/2015) and compared it to published data before the routine Tdap recommendation (01/01/2005-06/30/2010). We conducted clinical review of reports and available medical records. The clinical pattern of reports in the post-recommendation period was compared with the pattern before the routine Tdap recommendation. RESULTS: We found 392 reports of Tdap vaccination after the routine recommendation. One neonatal death but no maternal deaths were reported. No maternal or neonatal deaths were reported before the recommendation. We observed an increase in proportion of reports for stillbirths (1.5-2.8%) and injection site reactions/arm pain (4.5-11.9%) after the recommendation compared to the period before the routine recommendation for Tdap during pregnancy. We noted a decrease in reports of spontaneous abortion (16.7-1%). After the 2011 Tdap recommendation, in most reports, vaccination (79%) occurred during the third trimester compared to 4% before the 2011 Tdap recommendation. Twenty-six reports of repeat Tdap were received in VAERS; 13 did not report an AE. One medical facility accounted for 27% of all submitted reports. CONCLUSIONS: No new or unexpected vaccine AEs were noted among pregnant women who received Tdap after routine recommendations for maternal Tdap vaccination. Changes in reporting patterns would be expected, given the broader use of Tdap in pregnant women in the third trimester. Published by Elsevier Ltd.
BACKGROUND: In October 2011, the Advisory Committee on Immunization Practices (ACIP) issued updated recommendations that all pregnant women routinely receive a dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. OBJECTIVES: We characterized reports to the Vaccine Adverse Event Reporting System (VAERS) in pregnant women who received Tdap after this updated recommendation (2011-2015) and compared the pattern of adverse events (AEs) with the period before the updated recommendation (2005-2010). METHODS: We searched the VAERS database for reports of AEs in pregnant women who received Tdap vaccine after the routine recommendation (11/01/2011-6/30/2015) and compared it to published data before the routine Tdap recommendation (01/01/2005-06/30/2010). We conducted clinical review of reports and available medical records. The clinical pattern of reports in the post-recommendation period was compared with the pattern before the routine Tdap recommendation. RESULTS: We found 392 reports of Tdap vaccination after the routine recommendation. One neonatal death but no maternal deaths were reported. No maternal or neonatal deaths were reported before the recommendation. We observed an increase in proportion of reports for stillbirths (1.5-2.8%) and injection site reactions/arm pain (4.5-11.9%) after the recommendation compared to the period before the routine recommendation for Tdap during pregnancy. We noted a decrease in reports of spontaneous abortion (16.7-1%). After the 2011 Tdap recommendation, in most reports, vaccination (79%) occurred during the third trimester compared to 4% before the 2011 Tdap recommendation. Twenty-six reports of repeat Tdap were received in VAERS; 13 did not report an AE. One medical facility accounted for 27% of all submitted reports. CONCLUSIONS: No new or unexpected vaccine AEs were noted among pregnant women who received Tdap after routine recommendations for maternal Tdap vaccination. Changes in reporting patterns would be expected, given the broader use of Tdap in pregnant women in the third trimester. Published by Elsevier Ltd.
Authors: Pedro L Moro; Jorge Arana; Paige L Marquez; Carmen Ng; Faith Barash; Beth F Hibbs; Maria Cano Journal: Vaccine Date: 2019-05-30 Impact factor: 3.641
Authors: Jennifer L Liang; Tejpratap Tiwari; Pedro Moro; Nancy E Messonnier; Arthur Reingold; Mark Sawyer; Thomas A Clark Journal: MMWR Recomm Rep Date: 2018-04-27
Authors: Petra Zimmermann; Kirsten P Perrett; Nicole L Messina; Susan Donath; Nicole Ritz; Fiona R M van der Klis; Nigel Curtis Journal: EClinicalMedicine Date: 2019-07-26
Authors: Christine Elizabeth Jones; Anna Calvert; Jo Southern; Mary Matheson; Nick Andrews; Asma Khalil; Hannah Cuthbertson; Bassam Hallis; Anna England; Paul T Heath; Elizabeth Miller Journal: BMC Med Date: 2021-06-08 Impact factor: 8.775
Authors: Malini DeSilva; Flor M Munoz; Erick Sell; Helen Marshall; Alison Tse Kawai; Alisa Kachikis; Paul Heath; Nicola P Klein; James M Oleske; Fyezah Jehan; Hans Spiegel; Mirjana Nesin; Beckie N Tagbo; Anju Shrestha; Clare L Cutland; Linda O Eckert; Sonali Kochhar; Azucena Bardají Journal: Vaccine Date: 2017-12-04 Impact factor: 3.641